

Frank Jessen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7692108/publications.pdf>

Version: 2024-02-01

275
papers

27,571
citations

26610

56
h-index

6643

156
g-index

307
all docs

307
docs citations

307
times ranked

26418
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired self-awareness of cognitive deficits in Parkinson's disease relates to cingulate cortex dysfunction. <i>Psychological Medicine</i> , 2023, 53, 1244-1253.	2.7	7
2	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. <i>Alzheimer's and Dementia</i> , 2023, 19, 487-497.	0.4	25
3	Amyloid pathology but not <i>APOE</i> ϵ 4 status is permissive for tau-related hippocampal dysfunction. <i>Brain</i> , 2022, 145, 1473-1485.	3.7	17
4	Subjective cognitive decline in idiopathic Parkinson's disease: A systematic review. <i>Ageing Research Reviews</i> , 2022, 74, 101508.	5.0	8
5	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
6	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	1.4	14
7	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. <i>Neuron</i> , 2022, 110, 1009-1022.e4.	3.8	27
8	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1267-1282.	1.2	12
9	Difference in Amyloid Load Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Study from the SILCODE. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1573-1582.	1.2	0
10	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 545-555.	1.2	5
11	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
12	Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-15.	1.2	6
13	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	0.7	16
14	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
15	A Comparison of Operational Definitions for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1663-1678.	1.2	4
16	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
17	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 493-509.	1.2	14
18	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2021, 29, 102533.	1.4	15

#	ARTICLE	IF	CITATIONS
19	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 341-350.	4.0	18
20	Biomarker-Based Risk Prediction of Alzheimer's Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 601-617.	1.2	11
21	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 626974.	1.7	15
22	Identification of undiagnosed dementia cases using a web-based pre-screening tool: The MOPEAD project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1307-1316.	0.4	8
23	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. <i>Neurology</i> , 2021, 96, .	1.5	72
24	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
25	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. <i>Cerebral Cortex</i> , 2021, 31, 4901-4915.	1.6	12
26	Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. <i>Alzheimer's and Dementia</i> , 2021, . .	0.4	3
27	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1149-1159.	1.2	4
28	Editorial: Exploring Reliable Markers and Prediction Indexes for the Progression From Subjective Cognitive Decline to Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 760920.	1.7	1
29	Social Cognition in Patients with Amnesic Mild Cognitive Impairment and Mild Dementia of the Alzheimer Type. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1173-1186.	1.2	1
30	Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 740005.	1.7	4
31	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	3.0	35
32	A microRNA signature that correlates with cognition and is a target against cognitive decline. <i>EMBO Molecular Medicine</i> , 2021, 13, e13659.	3.3	29
33	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services" part 1 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 168.	3.0	26
34	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 191.	3.0	21
35	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
36	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1

#	ARTICLE	IF	CITATIONS
37	The effect of a mindfulness-based versus health self-management intervention on cognitive performance in older adults with subjective cognitive decline (SCD): The SCD-Well randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
38	Association between SCD-Plus features and GDS factors in subjective cognitive decline and healthy controls in the studies DELCODE and SILCODE. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
39	Characterization of the NIA-AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
40	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
42	Feasibility of short imaging protocols for [¹⁸ F]Pi2620 tau-PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
43	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer's disease: The first step towards comprehensive artificial intelligence. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
44	INSPIRATION: Study design and preliminary results of a cross-sectional risk AD-profiling study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
45	Prediction of amyloid-positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize number-needed-to-screen. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
46	Automated segmentation of the locus coeruleus in aging and Alzheimer's disease using 3T neuromelanin-sensitive MRI.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052564.	0.4	0
47	Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 501-511.	1.8	8
48	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 131.	3.0	17
49	Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer's Disease Dementia via Lead-Lag Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1005-1015.	1.2	0
50	Evaluation of evidence grades in psychiatry and psychotherapy guidelines. <i>BMC Psychiatry</i> , 2020, 20, 503.	1.1	0
51	Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 55.	4.4	107
52	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.4	43
53	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2020, 16, 1504-1514.	0.4	35
54	Comparison of Patient and Proxy Assessment of Patient-Centeredness in the Care of Coronary Heart Disease: A Cross Sectional Survey Using the PACIC-S11.1. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272097623.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 167.	3.0	64
56	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2020, 28, 102495.	1.4	17
57	Feasibility of mobile app-based assessment of memory functions: Insights from a citizen science study. <i>Alzheimer's and Dementia</i> , 2020, 16, e039149.	0.4	1
58	Anosognosia in Alzheimer's disease associated with tau accumulation and hypometabolism in frontal areas. <i>Alzheimer's and Dementia</i> , 2020, 16, e039416.	0.4	0
59	General practitioners' opinion on early and pre-dementia diagnosis of AD: A MOPEAD project survey in five European countries. <i>Alzheimer's and Dementia</i> , 2020, 16, e040357.	0.4	0
60	Altered resting state activity associated with anosognosia in Alzheimer's clinical syndrome: Findings from the DELCODE study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040416.	0.4	0
61	Gender differences in the perception of subjective vs. objective cognitive decline: Baseline data from the SCD-Well Trial. <i>Alzheimer's and Dementia</i> , 2020, 16, e040428.	0.4	0
62	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSF A β pathology: Data from the DELCODE Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044741.	0.4	1
63	Awareness of cognitive decline and CSF biomarkers in memory clinic patients: Results from the DELCODE study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044744.	0.4	0
64	Pre-screening models for patient engagement: The MOPEAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044796.	0.4	1
65	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e045349.	0.4	0
66	Psychotherapeutic interventions in individuals at risk for Alzheimer's dementia: A systematic review. <i>Alzheimer's and Dementia</i> , 2020, 16, e047269.	0.4	0
67	Cognitive, Genetic, Brain Volume, and Diffusion Tensor Imaging Markers as Early Indicators of Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1443-1453.	1.2	7
68	Prediction of dementia of Alzheimer type by different types of subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, 1745-1749.	0.4	14
69	Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 52.	3.0	22
70	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. <i>Brain Research Bulletin</i> , 2020, 161, 13-20.	1.4	3
71	Depression: an underrecognized target for prevention of dementia in Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, 160.	2.4	138
72	Bupropion for the Treatment of Apathy in Alzheimer Disease. <i>JAMA Network Open</i> , 2020, 3, e206027.	2.8	18

#	ARTICLE	IF	CITATIONS
73	Attention in subjective cognitive decline – Authors' reply. <i>Lancet Neurology</i> , The, 2020, 19, 566-567.	4.9	1
74	Minor neuropsychological deficits in patients with subjective cognitive decline. <i>Neurology</i> , 2020, 95, e1134-e1143.	1.5	58
75	The characterisation of subjective cognitive decline. <i>Lancet Neurology</i> , The, 2020, 19, 271-278.	4.9	627
76	Detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): A cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0243800.	1.1	5
77	Title is missing!. , 2020, 15, e0243800.		0
78	Title is missing!. , 2020, 15, e0243800.		0
79	Title is missing!. , 2020, 15, e0243800.		0
80	Title is missing!. , 2020, 15, e0243800.		0
81	Title is missing!. , 2020, 15, e0243800.		0
82	Title is missing!. , 2020, 15, e0243800.		0
83	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 66.	3.0	74
84	“Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia”. <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157.	0.4	23
85	Refining the understanding of typical Alzheimer disease. <i>Nature Reviews Neurology</i> , 2019, 15, 623-624.	4.9	3
86	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 610-618.	1.2	17
87	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 455-465.	1.2	15
88	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. <i>Journal of Neuroscience</i> , 2019, 39, 8788-8797.	1.7	64
89	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 8.	3.0	23
90	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease based on multicenter diffusion tensor imaging. <i>Journal of Neurology</i> , 2019, 266, 2465-2474.	1.8	35

#	ARTICLE	IF	CITATIONS
91	Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ϵ 4 carriers versus APOE ϵ 4 non-carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 50.	3.0	26
92	Level of education mitigates the impact of tau pathology on neuronal function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1787-1795.	3.3	16
93	The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
94	COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER'S DISEASE " THE NEXT STEP. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-1.	1.5	0
95	Personalized risk for clinical progression in cognitively normal subjects"the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	3.0	30
96	Quality of health care with regard to detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): study protocol. <i>BMC Psychology</i> , 2019, 7, 21.	0.9	10
97	Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF $A\beta$ levels. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 281-285.	1.2	56
98	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta$, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
99	ICAD122: ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER'S DEMENTIA. <i>Alzheimer's and Dementia</i> , 2019, 15, P101.	0.4	0
100	ICAD28: PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. <i>Alzheimer's and Dementia</i> , 2019, 15, P35.	0.4	0
101	ICAD16: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOID-POSITIVE SCD. <i>Alzheimer's and Dementia</i> , 2019, 15, P25.	0.4	0
102	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). <i>BMC Psychiatry</i> , 2019, 19, 423.	1.1	11
103	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.4	232
104	Neuronal correlates of delay discounting in healthy subjects and its implication for addiction: an ALE meta-analysis study. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 51-66.	1.1	35
105	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
106	Is function in instrumental activities of daily living a useful feature in predicting Alzheimer's disease dementia in subjective cognitive decline?. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 193-203.	1.3	41
107	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease"Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.4	28
108	Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD). <i>NeuroImage: Clinical</i> , 2019, 21, 101612.	1.4	35

#	ARTICLE	IF	CITATIONS
109	ICA€P161: 18Fâ€PI2620 TAUâ€PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTIâ€CENTER EVALUATION. Alzheimer's and Dementia, 2019, 15, P128.	0.4	3
110	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	6
111	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	0
112	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	1
113	Age-related functional changes in domain-specific medial temporal lobe pathways. Neurobiology of Aging, 2018, 65, 86-97.	1.5	118
114	One step towards dementia prevention. Lancet Neurology, The, 2018, 17, 294-295.	4.9	3
115	Wishes and preferences for an online lifestyle program for brain healthâ€”A mixed methods study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 141-149.	1.8	11
116	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
117	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	3.0	131
118	Neuroanatomical Characteristics Associated With Response to Deep Brain Stimulation of the Nucleus Basalis of Meynert for Alzheimerâ€™s Disease. Neuromodulation, 2018, 21, 184-190.	0.4	43
119	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
120	P3â€616: EICOSAPENTAENOIC ACID BUT NOT DOCOSAHEXAENOIC ACID IS ASSOCIATED WITH ALZHEIMER'S DISEASE RISK IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2018, 14, P1366.	0.4	0
121	P1â€879: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.4	0
122	P2â€534: STATUS QUO OF HEALTH LITERACY IN INDIVIDUALS AT RISK FOR DEVELOPING ALZHEIMER'S DISEASE: FIRST DATA OF A SYSTEMATIC REVIEW. Alzheimer's and Dementia, 2018, 14, P941.	0.4	0
123	P1â€311: RISK KNOWLEDGE OF MCI PATIENTS IN PREDICTIVE DIAGNOSIS OF ALZHEIMER'S DEMENTIA: PRELIMINARY DATA OF A MIXED METHOD APPROACHâ€”THE PREDADQOL STUDY. Alzheimer's and Dementia, 2018, 14, P410.	0.4	0
124	P3â€545: â€œMOVE ON UPâ€: THE MOBI ASSISTâ€PROGRAMME. Alzheimer's and Dementia, 2018, 14, P1331.	0.4	0
125	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.4	0
126	P2â€434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P879.	0.4	0

#	ARTICLE	IF	CITATIONS
127	P1â€¦12: ASSESSMENT OF SOCIAL COGNITIVE ABILITIES IN PATIENTS WITH MCI AND MILD AD COMPARED TO YOUNGER AND OLDER HEALTHY CONTROLS. Alzheimer's and Dementia, 2018, 14, P526.	0.4	0
128	P2â€¦455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.4	0
129	P3â€¦289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€¦SCD STUDY. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
130	FTS4â€¦01â€¦02: SUBJECTIVE AND VERY FIRST OBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1398.	0.4	0
131	P1â€¦028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.4	0
132	P3â€¦366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	0.4	0
133	ICâ€¦Pâ€¦155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.4	0
134	P3â€¦591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.4	8
135	P3â€¦122: <i>APOE</i>â€¦4 MODULATES LEVELS OF OMEGAâ€¦3 AND OMEGAâ€¦6 FATTY ACIDS IN ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1114.	0.4	0
136	The SCDâ€¦Well randomized controlled trial: Effects of a mindfulnessâ€¦based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 737-745.	1.8	26
137	F4â€¦08â€¦04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.4	0
138	P4â€¦074: COUNSELING AND DISCLOSURE IN RISK PREDICTION OF ALZHEIMER'S DEMENTIA: IMPACT ON MCI PATIENTS AND THEIR CAREGIVERSâ€¦THE PREDADQOL STUDY. Alzheimer's and Dementia, 2018, 14, P1462.	0.4	0
139	F1â€¦04â€¦03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P207.	0.4	0
140	P4â€¦068: LEVELS OF THE ASTROCYTEâ€¦DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. Alzheimer's and Dementia, 2018, 14, P1458.	0.4	1
141	P1â€¦458: LEVEL OF BRAIN RESERVE ASSOCIATED WITH SPATIAL EXTENT OF TAUâ€¦NEURODEGENERATION PATTERN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P494.	0.4	0
142	P2â€¦431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, Î²â€¦AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE). Alzheimer's and Dementia, 2018, 14, P877.	0.4	0
143	Exploring Genetic Associations of Alzheimerâ€¦'s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	1.7	12
144	Computerâ€¦assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	1.2	8

#	ARTICLE	IF	CITATIONS
145	Advance directives for future dementia can be modified by a brief video presentation on dementia care: An experimental study. PLoS ONE, 2018, 13, e0197229.	1.1	6
146	Informal caregivers' perspectives on health of and (potentially inappropriate) medication for (relatively) independent oldest-old people – a qualitative interview study. BMC Geriatrics, 2018, 18, 169.	1.1	8
147	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	1.2	26
148	P1159: RARE VARIANTS IN <i>PLCG2</i> , <i>ABI3</i> , AND <i>TREM2</i> GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?. Alzheimer's and Dementia, 2018, 14, P337.	0.4	0
149	P304: MODELS OF PATIENT ENGAGEMENT IN ALZHEIMER'S DISEASE (MOPEAD): A EUROPEAN MULTINATIONAL PROJECT TO DEVELOP AND TEST INNOVATIVE PATIENT ENGAGEMENT STRATEGIES. Alzheimer's and Dementia, 2018, 14, P1197.	0.4	0
150	Neurocognitive disorders in ICD-11: the debate and its outcome. World Psychiatry, 2018, 17, 229-230.	4.8	12
151	Not all, but specific types of cognitive complaints predict decline to MCI. Neurology, 2018, 91, 153-154.	1.5	6
152	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	1.7	34
153	Prospective Associations between Single Foods, Alzheimer's Dementia and Memory Decline in the Elderly. Nutrients, 2018, 10, 852.	1.7	57
154	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813.	1.2	19
155	Impact of coronary heart disease on cognitive decline in Alzheimer's disease: a prospective longitudinal cohort study in primary care. British Journal of General Practice, 2017, 67, e111-e117.	0.7	33
156	Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 56, 1185-1196.	1.2	37
157	Predicting primary progressive aphasia with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	1.4	42
158	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychology Review, 2017, 27, 245-257.	2.5	97
159	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	1.4	64
160	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 939-950.	1.2	74
161	Reduced future-oriented decision making in individuals with subjective cognitive decline: A functional MRI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 222-231.	1.2	34
162	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87

#	ARTICLE	IF	CITATIONS
163	In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. <i>NeuroImage</i> , 2017, 163, 150-159.	2.1	117
164	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
165	[P2â€“200]: <i>IN VIVO</i> TAUOPATHY MEASURED WITH [18F]â€“AVâ€“1451 IS DIFFERENTIALLY RELATED TO CSF BIOMARKERS OF TAU IN ALZHEIMER'S DISEASE: THE INFLUENCE OF AMYLOID DEPOSITION. <i>Alzheimer's and Dementia</i> , 2017, 13, P683.	0.4	0
166	[P3â€“395]: USING NEUROMELANINâ€“SENSITIVE MRI TO CHARACTERISE THE STRUCTURAL INTEGRITY OF THE HUMAN LOCUS COERULEUS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1114.	0.4	0
167	[P1â€“320]: INTERPRETATIVE PHENOMENOLOGICAL ANALYSIS OF COGNITIVE COMPLAINTS REVEALS COMMONALITIES AND DIFFERENCES BETWEEN MEMORYâ€“CLINIC PATIENTS, DEPRESSIVE PATIENTS, AND HEALTHY ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P377.	0.4	0
168	[P2â€“074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. <i>Alzheimer's and Dementia</i> , 2017, 13, P634.	0.4	0
169	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.4	375
170	Which types of mental work demands may be associated with reduced risk of dementia?. <i>Alzheimer's and Dementia</i> , 2017, 13, 431-440.	0.4	33
171	[Icâ€“080]: USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARKER FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P66.	0.4	2
172	[P2â€“390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P779.	0.4	1
173	[P3â€“164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE CÎ³2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P997.	0.4	0
174	[P3â€“218]: TAU PLASMA LEVELS IN SUBJECTIVE COGNITIVE DECLINE: RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1021.	0.4	1
175	[P3â€“372]: DOMAINâ€“SPECIFIC MNEMONIC DISCRIMINATION IN AGEING AND EARLY STAGES OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1100.	0.4	0
176	[P3â€“393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER'S DISEASE BASED ON MULTICENTER RESTINGâ€“STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1112.	0.4	0
177	[P3â€“437]: LATENTâ€“FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1136.	0.4	2
178	[P3â€“528]: PROSPECTIVE ASSOCIATIONS BETWEEN VITAMINS, METABOLITES, AND OVERALL DEMENTIA IN THE OLDESTâ€“OLD. <i>Alzheimer's and Dementia</i> , 2017, 13, P1180.	0.4	2
179	[P3â€“566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1195.	0.4	0
180	[P1â€“122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER'S DISEASE, AND NEURAL NETWORKS. <i>Alzheimer's and Dementia</i> , 2017, 13, P287.	0.4	2

#	ARTICLE	IF	CITATIONS
181	[P4â€“139]: APPLICATION OF THE â€“A/T/Nâ€“™ BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P1310.	0.4	0
182	[P4â€“166]: EVIDENCE FOR AMYLOID PATHOLOGY IN SCDâ€“DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1325.	0.4	0
183	[P4â€“223]: THE PHENOMENOLOGY AND THE NEURONAL CORRELATES OF EPISODIC FUTURE IMAGINATION IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE AND HEALTHY CONTROLS. Alzheimer's and Dementia, 2017, 13, P1354.	0.4	0
184	[P4â€“248]: QUALITY ASSURANCE IN DELCODE: A MULTIâ€“CENTER NEUROIMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P1372.	0.4	0
185	[ICâ€“Pâ€“030]: CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSFâ€“TAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P28.	0.4	0
186	[ICâ€“Pâ€“139]: THE PHENOMENOLOGY AND THE NEURONAL CORRELATES OF EPISODIC FUTURE IMAGINATION IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE AND HEALTHY CONTROLS. Alzheimer's and Dementia, 2017, 13, P105.	0.4	0
187	[TDâ€“Pâ€“020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.4	0
188	[P1â€“554]: OPTIMAL HARMONIZATION OF COGNITIVE MEASURES ENHANCES THE DETECTION OF GENETIC EFFECTS ON ALZHEIMER'S DISEASE PROGRESSION: A COMPARISON OF SIX STATISTICAL APPROACHES IN 1796 MCI PATIENTS FROM THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P506.	0.4	0
189	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	3.0	58
190	A Reduction in Delay Discounting by Using Episodic Future Imagination and the Association with Episodic Memory Capacity. Frontiers in Human Neuroscience, 2017, 10, 663.	1.0	25
191	Caspase-8, association with Alzheimerâ€™s Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	1.1	38
192	Differential Risk of Incident Alzheimerâ€™s Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2016, 54, 1135-1146.	1.2	70
193	In vivo Patterns of Tau Pathology, Amyloid-Î² Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 465-471.	1.2	93
194	P3â€“237: 1Hâ€“MRS in Subjects with SCD, MCI and Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P917.	0.4	0
195	ICâ€“Pâ€“046: Abnormal Functional Connectivity Within Default Mode Network in Persons With Subjective Cognitive Decline: Selfâ€“Reflection of Own Memory Deficits?. Alzheimer's and Dementia, 2016, 12, P39.	0.4	3
196	P2â€“087: Genetic Determinants of Alzheimer's Disease Progression: Exploratory Analysis of International Genomics of Alzheimer Project (IGAP) Genetic Markers in MMSE Rate of Decline and GDS. Alzheimer's and Dementia, 2016, 12, P642.	0.4	0
197	P2â€“339: Abnormal Functional Connectivity within Default Mode Network in Persons with Subjective Cognitive Decline: Selfâ€“Reflection of Own Memory Deficits?. Alzheimer's and Dementia, 2016, 12, P772.	0.4	3
198	P2-348: Impact of Non-Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials. , 2016, 12, P777-P777.		0

#	ARTICLE	IF	CITATIONS
199	P2â€³51: â€“Healthy Dietâ€™ and Cognitive Status in the Oldest Old. <i>Alzheimer's and Dementia</i> , 2016, 12, P779.	0.4	0
200	IC-P-143: 1H-MRS in Subjects With SCD, MCI and AD. , 2016, 12, P106-P106.		0
201	P4â€³53: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€“AD in Memory Clinic and Communityâ€“Based Cohorts. <i>Alzheimer's and Dementia</i> , 2016, 12, P1073.	0.4	1
202	P1-010: Face Name Associative Recognition is Associated with Alzheimerâ€™s Disease Biomarkers in Patients with Subjective Cognitive Decline. , 2016, 12, P402-P403.		0
203	P1â€³20: Exploring International Genomics of Alzheimerâ€™s Project (IGAP) Genetic Markers' Effect on Age at Onset of Dementia in Alzheimerâ€™s Disease Patients. <i>Alzheimer's and Dementia</i> , 2016, 12, P448.	0.4	0
204	Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 934-939.	1.7	89
205	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. <i>Epigenomics</i> , 2016, 8, 593-598.	1.0	5
206	P2â€³35: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. <i>Alzheimer's and Dementia</i> , 2016, 12, P770.	0.4	0
207	Longitudinal predictors of informal and formal caregiving time in community-dwelling dementia patients. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016, 51, 607-616.	1.6	46
208	TREM2 rare variant p.R47H is not associated with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 109-111.	1.1	17
209	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
210	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.4	50
211	Deep Brain Stimulation for Tourette-Syndrome: A Systematic Review and Meta-Analysis. <i>Brain Stimulation</i> , 2016, 9, 296-304.	0.7	185
212	Mortality in Individuals with Subjective Cognitive Decline: Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). <i>Journal of Alzheimer's Disease</i> , 2015, 48, S33-S42.	1.2	20
213	Elevated HbA1c is Associated with Increased Risk of Incident Dementia in Primary Care Patients. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1203-1212.	1.2	52
214	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	1.2	317
215	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
216	Feature Binding Deficits in Subjective Cognitive Decline and in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S161-S170.	1.2	41

#	ARTICLE	IF	CITATIONS
217	Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S99-S107.	1.2	40
218	Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S1-S3.	1.2	18
219	The Latent Dementia Phenotype \hat{I} is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	1.2	23
220	Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0132227.	1.1	55
221	Cognitive performance before and after the onset of subjective cognitive decline in old age. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 194-205.	1.2	110
222	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	1.5	27
223	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	1.5	125
224	Cortical Thinning in Individuals with Subjective Memory Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 139-146.	1.2	66
225	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.5	41
226	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 27.	3.0	13
227	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	13.7	58
228	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.4	104
229	Complex coevolution of depression and health-related quality of life in old age. <i>Quality of Life Research</i> , 2015, 24, 2713-2722.	1.5	20
230	Computational dissection of human episodic memory reveals mental process-specific genetic profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4939-48.	3.3	16
231	Genetic Analysis of Association Between Calcium Signaling and Hippocampal Activation, Memory Performance in the Young and Old, and Risk for Sporadic Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 1029.	6.0	23
232	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1177.	3.8	2
233	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
234	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.4	56

#	ARTICLE	IF	CITATIONS
235	Longitudinal Predictors of Institutionalization in Old Age. PLoS ONE, 2015, 10, e0144203.	1.1	128
236	Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer's Disease. Current Alzheimer Research, 2015, 12, 266-277.	0.7	45
237	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. PLoS ONE, 2014, 9, e100812.	1.1	41
238	SUCLG2 identified as both a determinant of CSF A β 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	1.4	45
239	Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 3-7.	1.8	116
240	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
241	Converging Genetic and Functional Brain Imaging Evidence Links Neuronal Excitability to Working Memory, Psychiatric Disease, and Brain Activity. Neuron, 2014, 81, 1203-1213.	3.8	86
242	N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: A systematic review. European Neuropsychopharmacology, 2014, 24, 1659-1675.	0.3	49
243	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	1.5	34
244	The CERAD Neuropsychological Assessment Battery Total Score Detects and Predicts Alzheimer Disease Dementia with High Diagnostic Accuracy. American Journal of Geriatric Psychiatry, 2014, 22, 1017-1028.	0.6	56
245	The Costs of Dementia From the Societal Perspective: Is Care Provided in the Community Really Cheaper than Nursing Home Care?. Journal of the American Medical Directors Association, 2014, 15, 117-126.	1.2	35
246	Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.4	47
247	Gray matter atrophy pattern in elderly with subjective memory impairment. Alzheimer's and Dementia, 2014, 10, 99-108.	0.4	129
248	AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer's and Dementia, 2014, 10, 76-83.	0.4	414
249	P1-022: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH CSF AMYLOID B 1-42, DEPRESSIVE SYMPTOMS AND EPISODIC MEMORY PERFORMANCE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. , 2014, 10, P312-P312.		0
250	O4-04-04: TOWARD FINE MAPPING AND FUNCTIONAL CHARACTERIZATION OF GENOME-WIDE ASSOCIATION STUDY-IDENTIFIED LOCUS RS74615166 (TRIP4) FOR ALZHEIMER'S DISEASE. , 2014, 10, P257-P258.		1
251	Structural and Functional Magnetic Resonance Imaging. PET Clinics, 2013, 8, 407-430.	1.5	1
252	N-Acetylaspartylglutamate (NAAG) and N-Acetylaspartate (NAA) in Patients With Schizophrenia. Schizophrenia Bulletin, 2013, 39, 197-205.	2.3	63

#	ARTICLE	IF	CITATIONS
271	Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 27-31.	1.8	243
272	Identical distribution of the α 2-macroglobulin pentanucleotide deletion in subjects with alzheimer disease and controls in a German population. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 775-777.	2.4	18
273	Gene-gene interaction between interleukin-6 and α 2-macroglobulin influences the risk for Alzheimer's disease. <i>Annals of Neurology</i> , 2000, 47, 138-139.	2.8	14
274	A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 45, 666-668.	2.8	205
275	Functional MRI of cerebral activation during encoding and retrieval of words. , 1999, 8, 157-169.		37